Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392027 · ClinicalTrials.gov registry record · NA
Biospecimens for Identification of Diseases of the Pancreas.
A NA study of Pancreatic Cancer and Chronic Pancreatitis, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 712
- Enrollment target
- 1
- Study location
NCT01392027: Completed NA study of Pancreatic Cancer and Chronic Pancreatitis, sponsored by University of Michigan.
NCT01392027 is a NA study of Pancreatic Cancer and Chronic Pancreatitis that has completed, run by University of Michigan. The registered enrollment target is 712 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01392027, a NA study of Pancreatic Cancer and Chronic Pancreatitis, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 712 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed project is designed to collect data and specimens from patients/subjects presenting to the University of Michigan with a disease affecting the pancreas (or specific control populations). This protocol is focused on collecting data, blood samples, and tissue on subjects with pancreatic diseases, including pancreatic cancer, pancreatic cysts, pancreatitis, diabetic controls, jaundice/biliary obstruction controls, and otherwise healthy controls. We are collecting up to 50 mls of blood for research purposes only. Plasma, serum and buffy coat are collected and stored according to strict SOPs.
Primary Outcome
To create a set of cases and controls to validate a novel glycoprotein panel for non-invasive or early detection of pancreatic cancer.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Michigan
- Univerisity of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 712 participants |
| Start Date | 2011-04 |
| Est. Completion | 2017-08-31 |
| Phase | NA |
What the finished NCT01392027 record still lists
NCT01392027 is an interventional study that assigns participants to a tested intervention. The registered 712 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (82% higher).
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT01392027 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01392027 about?
NCT01392027 is a clinical study titled "Biospecimens for Identification of Diseases of the Pancreas.". This proposed project is designed to collect data and specimens from patients/subjects presenting to the University of Michigan with a disease affecting the pancreas (or specific control populations). This protocol is focused on collecting data, blood samples, and tissue on subjects with pancreatic ...
What is the current status of trial NCT01392027?
This trial is currently completed. It is a NA study. The enrollment target is 712 participants. The study started on 2011-04. Estimated completion is 2017-08-31.
What conditions does trial NCT01392027 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Chronic Pancreatitis, Type II Diabetes, Healthy Control, Pancreatic Cysts.
What interventions are being tested in trial NCT01392027?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT01392027?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01392027 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01392027's enrollment target sits among peer trials
712 19th of 278 higher than 260 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia